Quick Answer
LIGAND PHARMACEUTICALS INC reported Revenue From Contract With Customer Excluding Assessed Tax of $268.09 million for the year ending 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +60.4% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from LIGAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), LIGAND PHARMACEUTICALS INC's Revenue From Contract With Customer Excluding Assessed Tax has grown by 146.0%.
- Historical annual values: Fiscal year 2025: $268.09 million | Fiscal year 2024: $167.13 million | Fiscal year 2023: $131.31 million | Fiscal year 2022: $196.25 million | Fiscal year 2021: $241.54 million | Fiscal year 2020: $163.56 million | Fiscal year 2019: $120.28 million | Fiscal year 2018: $251.45 million | Fiscal year 2017: $141.10 million | Fiscal year 2016: $108.97 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: